David Cirelli

Establishing <i>in vitro in vivo</i> correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics

Lindsay B. Avery, Jason Wade, Mengmeng Wang et al. · mAbs · 2017 · 97 citations · Full text

Immunocytochemical Technique, Immunology, Pathology +21

Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells

Yao‐Te Hsieh, Poonam Aggarwal, David Cirelli et al. · Journal of Immunological Methods · 2016 · 43 citations

Fcγriiia Effector Cells, Adaptive Immune System, Medicine +13

The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists’ Perspective

Lavinia M. Lewis, Advait Badkar, David Cirelli et al. · Journal of Pharmaceutical Sciences · 2022 · 39 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +5

Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2

Brian Gau, Andrew Dawdy, Hanliu Leah Wang et al. · Scientific Reports · 2023 · 34 citations · Full text

Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity

Sandeep Kumar, Kirk Roffi, Dheeraj S. Tomar et al. · Protein Engineering Design and Selection · 2018 · 30 citations · Full text

Immunocytochemical Technique, Engineering, Immunology +20